Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.
Milind Javle(The University of Texas MD Anderson Cancer Center), Ghassan K. Abou‐Alfa(Memorial Sloan Kettering Cancer Center), Wei Peng Yong(National University of Singapore), Suebpong Tanasanvimon(Thai Red Cross Society), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Robin Kate Kelley(UCSF Helen Diller Family Comprehensive Cancer Center), Stacie Peacock Shepherd(QED Technologies (United States)), Philip Agop Philip(Wayne State University), Lipika Goyal(Stanford Medicine), Susan Moran(QED Technologies (United States)), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Sameek Roychowdhury(The Ohio State University Wexner Medical Center), Amit Pande(QED Technologies (United States)), Ai Li(QED Technologies (United States)), Saeed Sadeghi(University of California, Los Angeles), Michael Bitzer(University Children's Hospital Tübingen), Dirk Waldschmidt, Ivan Borbath
Cited by 86
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Landscape of Microsatellite Instability Across 39 Cancer Types
|JCO Precision Oncology|2017|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k